Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230042/S010

Optune Lua

Novocure, GmbH · Decision date Oct 26, 2026

MEDTECHLEDGER EXPLANATIONP230042/S010

What did the FDA decide?

The FDA issued a 30-Day Notice decision for Novocure GmbH's Optune Lua (P230042/S010) on October 26, 2026, approving changes to the sterilization load configuration. The supplement type is a 30-Day Notice, and the stated supplement reason is a process change involving the manufacturer, sterilizer, packager, or supplier.

This supplement does not represent a new approval of the entire Optune Lua system or a new indication. The source statement identifies the device category as electrical tumor treatment fields for non-small cell lung cancer, but no clinical effectiveness or safety conclusions are provided in the decision record. Specific details about the exact sterilization load configuration change are absent from the available fields.

FDA approval order statement

approval for changes to the sterilization load configuration.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Anesthesiology
Decision date
Oct 26, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230042/S010
Regulatory pathway
PMA supplement
Product code
SDA
Decision code
OK30
Decision date
Oct 26, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Electrical tumor treatment fields for non-small cell lung cancer.

Product code
SDA
FDA device class
3

For the original device and its historical approval scope, see PMA P230042. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230042/S010 received

    Application receipt date recorded by FDA.

  2. P230042/S010 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P230042. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230042

Product / regulatory recordCompanyPathwayDecision dateSource
Optune LuaP230042
Novocure, GmbHPMA approvalOct 15, 2024FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Novocure, GmbH

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Neuhofstrasse 21, Baar, 6340

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records